INTRODUCTION {#sec1-1}
============

The protozoan *Entamoeba histolytica* is the causative agent of amebiasis. There are approximately 50 million cases of amebiasis per year worldwide, and it kills nearly 100 thousand people annually.\[[@ref1]\] Amebiasis is the most severe disease caused by protozoans that afflict the human intestine and the second leading cause of death among parasitic diseases.\[[@ref2]\] It is characterized by two major clinical syndromes, amebic colitis and amebic liver abscess.\[[@ref3]\] The importance of amebiasis stems from its widespread geographical distribution, its high incidence, and its association, in some cases, with severe and potentially fatal pathologies. It therefore remains a public health problem in developing countries despite the existence of medications.\[[@ref4]\]

*E. histolytica* was first described over 130 years ago in Russia by Lösch in 1875, as cited by Jackson (1998),\[[@ref5]\] and was formally named in 1903 by Schaudinn, as cited by Clark (1998).\[[@ref6]\] In an attempt to explain the high prevalence of asymptomatic infected individuals, the DualistTheory was proposed by Brumpt (1925), as cited by Walsh (1986); this theory proposed the existence of two amebas that were morphologically identical but biologically distinct.\[[@ref7]\] It was believed, however, that only *E. histolytica* should be able to penetrate tissues and produce invasive amebiasis. Subsequently, *E. histolytica* was separated into two distinct groups through isoenzyme electrophoresis: Pathogenic and non-pathogenic (NP), according to Brumpt 1925, as cited by Sargeaunt *et al*. (1978).\[[@ref8]\] The NP species would then explain the prevalence of asymptomatic disease in approximately 90% of infected individuals worldwide.\[[@ref7]\] The definitive proof that these two groups represented distinct species was obtained by deoxyribonucleic acid (DNA) analysis,\[[@ref9]\] and the new species was called *Entamoeba dispar*, by Brumpt 1925, as cited by Diamond and Clark (1993).\[[@ref10]\] The isoenzyme profiles, the differences in gene sequences, and the use of monoclonal antibodies confirmed the existence of two distinct species that have since been officially recognized by the World Health Organization (WHO).\[[@ref1]\] Currently, it is estimated that *E. histolytica* and *E. dispar* infect approximately 12% of the world population, with infections with the latter being substantially more common and with infections with *E. histolytica* possibly representing 1% of infections.\[[@ref1]\]

To differentiate infection by *E. histolytica* from infection by *E. dispar*, parasite antigen detection in stool samples\[[@ref11]\] and gene segment amplification in both stool and amebic liver abscess samples\[[@ref12]\] have been used. Epidemiological surveys have shown that most asymptomatic individuals infected by one of these species are colonized by *E. dispar*. However, in some regions, there is a high prevalence of *E. histolytica* in asymptomatic individuals and in patients with diarrhea.\[[@ref13][@ref14][@ref15]\] Studies on the genetic variation among ameba species provide important clues to explain the different clinical presentations of *E. histolytica* infection and provide data on the geographical distribution and mobility of epidemiologically important strains. Studies on the epidemiology of amebiasisin endemic areas have used molecular approaches to characterize the prevalent species of *Entamoeba* in human infection. These studies have attempted to correlate the different species and sub-populations with the diverse spectrum of clinical forms: (a) Symptomatic infections caused by *E. histolytica* (intestinal or extra-intestinal amebiasis); (b) asymptomatic *E. dispar* infections; (c) mixed asymptomatic infections caused by *E. histolytica* and *E. dispar*; and (d) asymptomatic *E. histolytica* infections.\[[@ref16]\]

With the recognition of the species *E. dispar* in 1997,\[[@ref1]\] several studies were conducted comparing this species with *E. histolytica*. *E. dispar* is morphologically similar to *E. histolytica* and has been considered as a distinct species based on isoenzyme patterns of amebas isolated from asymptomatic patients and those with invasive disease.\[[@ref8]\] The two *Entamoeba* species have nearly identical sets of genes encoding the major virulence factors. However, *E. histolytica* secretes approximately 10 to 1,000 times more cysteine proteases than *E. dispar*.\[[@ref17]\] The activity of *E. dispar* amebaporesis approximately one-third of that observed in *E. histolytica*.\[[@ref18]\] Furthermore, the Gal/GalNac lectin of *E. dispar* shows homology with two members of the heavy-chain family and four of the light-chain family in comparison to the *E. histolytica* lectin, leading to reduced adhesion and cytotoxicity *in vitro*.\[[@ref19]\]

Before its identification as a separate species, *E. dispar* was described as NP *E. histolytica*.\[[@ref10]\] Experimental studies involving NP *E. histolytica* failed to demonstrate its ability to produce significant lesions in laboratory animals.\[[@ref20][@ref21]\] Moreover, after the description of *E. dispar*, experimental research continued to show similar results. Espinosa-Cantellano *et al*., inoculated 5 × 10^5^ and 5 × 10^6^ *E. dispar* trophozoites in hamsters by the intra-hepatic route. Seven days after infection, the authors observed only focal inflammatory infiltrate with no formation of necrosis and granuloma.\[[@ref22]\] These findings, coupled with *in vitro* observations that *E. dispar* secretes toxic products in lower amounts and with lower activity than *E. histolytica*, reinforced the idea that *E. dispar* was commensal and thus incapable of generating human and experimental lesions. In fact, the axenic *E. dispar* SAW 760 strain produced a milder cytopathic effect on MDCK epithelial cells compared to that produced by *E. histolytica*.\[[@ref23]\]

The prevalence of *E. dispar* is not known. It is speculated that this species is responsible for most infections that were previously considered to be associated with *E. histolytica*. Studies worldwide show a higher prevalence of *E. histolytica* in developing countries; however, even in these countries, the prevalence of *E. dispar* is high.\[[@ref15][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32][@ref33][@ref34]\]

In Brazil, amebiasis is an important cause of morbidity.\[[@ref35][@ref36]\] *E. histolytica* is most prevalent in Manaus, where it infects 6.8% of the population,\[[@ref37]\] in Fortaleza, where it infects 14.9% of the low-income population,\[[@ref38]\] and in Belém, where it infects 29.5% of individuals living in the metropolitan area.\[[@ref39]\] In the remaining areas of the country, studies show a higher prevalence of *E. dispar*. In Pernambuco, Belo Horizonte (Minas Gerais), and Salvador (Bahia), only *E. dispar* was detected, with the exception of Minas Gerais. Our group has found an infection rate of nearly 5% with *E. histolytica*/*E. dispar* in communities of great Belo Horizonte.\[[@ref40]\] To date, 99% of these infections have been associated with *E. dispar* (unpublished data).

*E. dispar* is considered non-invasive and thus related to asymptomatic infections. In Brazil, non-dysenteric colitis represents a very frequent clinical presentation. The ameba isolates belonging to this group were analyzed by isoenzymes and PCR and identified as *E. dispar*. Our group was the first to identify *E. dispar* isolated from symptomatic cases.\[[@ref41][@ref42]\] The strains isolated in these cases were also able to infect experimental animals. As noted earlier, the first experimental studies involving NP *E. histolytica* (*E. dispar*) did not succeed in reproducing the amebic lesions. However, since 2000, studies published using xenic *E. dispar* strains isolated in Brazil began to show results different than those observed in previous reports. *E. dispar* strains isolated from patients living in the North and Southeast regions of Brazil were inoculated in the liver (5 × 10^4^ trophozoites) and cecum (1 × 10^6^ trophozoites) of hamsters and rats, respectively.\[[@ref43]\] All animals showed hepatic and intestinal lesions similar to those caused by *E. histolytica*, as well as the presence of trophozoites. The same was reported by Costa *et al*., after inoculating the liver of hamsters with 2.5 × 10^5^ trophozoites of other *E. dispar* strains also isolated from symptomatic and asymptomatic individuals in Brazil.\[[@ref44]\] Inoculation of the microbiota of each strain in control hamsters did not lead to liver lesions or produced only discrete purulent lesions, indicating that *E. dispar* trophozoites were responsible for the development of liquefactivenecrosis. Unlike the xenic strains, the use of axenic\[[@ref22]\] and monoxenic\[[@ref44][@ref45]\] strains of *E. dispar* failed to produce amebic abscesses, demonstrating the importance of bacterial association to acquire pathogenicity through unknown mechanisms. Recently, two other studies described what has been observed since 2000. Similar to the MCR strain, the experimental amebic liver abscess was reproduced in hamsters inoculated with xenic *E. dispar* strains also isolated from Brazilian asymptomatic patients.\[[@ref46][@ref47]\]

Research on the genetic diversity of *E. histolytica* and *E. dispar* in individuals with asymptomatic infection or invasive disease has shown high polymorphism of both Entamoeba species.\[[@ref16][@ref48][@ref49]\] Evidence for genetic diversity has been demonstrated through differences in the genotypes of *E. histolytica* isolated from stool and amebic liver abscess samples from the same patient.\[[@ref50]\] Other authors also detected different genotypes of *E. histolytica* trophozoites isolated from two distinct amebic liver abscesses from the same patient.\[[@ref51]\] As with certain *E. histolytica* strains, *E. dispar* strains may also exhibit varied biological behavior as a result of genetic diversity.\[[@ref43]\]

The use of more precise methods for quantifying amebic lesions showed that the liver abscess produced by the *E. dispar* MCR strain is as important and significant as that produced by the *E. histolytica* EGG strain.\[[@ref52]\] It is noteworthy that although the EGG strain was isolated from a symptomatic patient presenting dysenteric colitis and amebic abscess, the MCR strain was isolated from an asymptomatic patient. The kinetics of amebic liver abscess produced by a single *E. dispar* strain was studied over 8 days of infection, during which it was possible to describe changes such as the different phases of epithelioid granuloma, thrombosis and apoptosis.\[[@ref53]\] Although polyclonal antibodies were used in these two studies, immunohistochemical identification of *E. dispar* trophozoites greatly aided the counting of parasites and the qualitative and quantitative assessment of lesions associated with parasitism.

Our group inoculated the *E. dispar* MCR strain into the liver and cecum of different hosts to evaluate their susceptibility. We found that the hamster is the fittest animal to develop an abscesss by *E. dispar* (100% of challenged animals) and that both the mouse and ther at presented amebiccolitis in approximately 70% of cases (unpublished data).

By studying the *in vivo* binding of antibodies and complement to trophozoites of the MCR strain, we observed that trophozoite binding and destruction was higher than in animals inoculated with the *E. histolytica* EGG strain.\[[@ref54]\] Together with the larger amounts of *E. dispar* trophozoite debris observed, these findings confirmed the lower ability of this species to escape the action of the immune system. The joint study of MCR and EGG strains provided a better understanding of the relationship between the immune system and the development of amebic liver abscess. Regarding the virulence and pathogenicity inherent to each species, antibodies, complement, macrophages, and neutrophils seem to interfere in the selection of more resistant trophozoites and in the development of amebic liver abscesses.\[[@ref54][@ref55]\]

The explanation of the acquisition of pathogenicity of the *E. dispar* strains may lie in their interaction with bacteria. The observation that these lesions were obtained only after the association of bacteria with *E. dispar* suggest that the bacteria may be causing early injuries that favor the proliferation of and tissue invasion by trophozoites, by increasing the expression of virulence factors and/or by incorporating genes. In fact, the symbiosis between bacteria and *E. histolytica* or *E. dispar* may modulate phenotypic changes and virulence properties of ameba.\[[@ref53][@ref56][@ref57]\]

A recent *in vitro* study showed that the increased virulence of the *E. histolytica* HM1: MSS strain was mediated by the presence of pathogenic entero bacteria. In this study, the researchers observed that the phagocytosis of *Shigella dysenteriae* and enteropathogenic *Escherichia coli* (EPEC) by *E. histolytica* trophozoites increased the cytopathic effect of trophozoites on epithelial cells as well as the cysteine protease activity and the expression of Gal/GalNAc-specific lectin. The authors also suggest that infection with enterobacteria may render the intestine epithelial cells more susceptible to the virulence mechanisms of *E. histolytica*.\[[@ref58]\]

Although *E. dispar* is considered commensal for humans, evidence shows that additional in-depth studies are required to address this issue. *E. dispar* has been isolated from patients presenting symptoms of non-dysenteric colitis\[[@ref41][@ref42]\] and from a patient with dysenteric colitis.\[[@ref59]\] Moreover, DNA sequences of *E. dispar* were detected and genotyped in samples from patients with amebic liver abscess, suggesting that *E. dispar* may also be involved in the development of lesions in the human intestine and liver.\[[@ref16]\]

Given the evidence that *E. dispar* can produce significant experimental lesions in the presence of bacteria, along with the high frequency of intestinal co-infections that affect millions of people annually, we believe that the most important steps are further in-depth studies on the relationship between *E. dispar* and bacteria. Thus, we began a preliminary analysis of the possible interference of *Salmonella typhimurium* infection (intragastric intubation of 10^8^ colony-forming units (CFUs) at 14 hours before the amebic infection) with the MCR strain of *E. dispar* (intracecal inoculation of 5 × 10^5^ trophozoites) for approximately 7 days. In Wistar rats infected with *E. dispar* only, intestinal lesions were characterized by areas of mucosal destruction and submucosal inflammation (mixed inflammatory infiltrate, hyperemia, and edema), which sometimes reached the muscle and serosa. The presence of bacteria increased the intestinal necrosis area and the intensity of the inflammatory response. We scanned the necrotic areas through a JVC TK-1270/RGB micro-camera and measured these areas using the KS300 software in the Carl Zeiss image analyzer.\[[@ref52]\] We morphometrically confirmed the development of a larger lesion area of the cecal mucosa in animals infected with both *E. dispar* and *S. typhimurium* (139,822 ± 30,089 μm^2^ ) compared to the lesion area of the cecal mucosa in animals infected with *E. dispar* only (50,657 ± 5,131 μm^2^ ) (*P* \< 0.0001). Infection of animals with *S. typhimurium* alone did not lead to the destruction of the colonic mucosa as observed in *E. dispar* infection, and only the presence of areas of epithelial shedding was observed. The inflammation caused by *S. typhimurium* alone in the sub-mucosal layer was substantially reduced compared to that observed in animals co-infected with *E. dispar* and *S. typhimurium*. Future molecular biology studies will determine whether the bacteria favored the expression of amebic virulence factors and/or whether the epithelial lesions alone caused by bacteria favor trophozoite adhesion and invasion.
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